Introduction {#section1-2374289518816502}
============

Acute kidney injury (AKI) is a common comorbidity and affects up to 20% of all hospitalized patients.^[@bibr1-2374289518816502]^ The KDIGO (Kidney Disease: Improving Global Outcomes) guidelines are the most widely accepted evidence-based diagnostic criteria for AKI. The diagnosis and assessment of AKI severity is dependent on incremental rise in serum creatinine (SCr) above the patient's baseline value within a specified duration.^[@bibr1-2374289518816502]^ Increasing severity of AKI is associated with longer length of stay (LOS), costs of care, resource utilization, and in-hospital mortality.^[@bibr2-2374289518816502][@bibr3-2374289518816502]-[@bibr4-2374289518816502]^ Hence, it is imperative to diagnose and manage AKI at the earliest possible stage during an inpatient admission. Since AKI can occur on virtually every hospital service, this comorbidity must be recognized by practitioners across a broad array of clinical specialties.

Although nephrologists are well-versed with KDIGO criteria, most AKI diagnoses, especially early-stage disease, are made by nonspecialist physicians.^[@bibr3-2374289518816502]^ Physician recognition of AKI remains poor because of inability to apply KDIGO criteria consistently in routine hospital settings, limited clinical awareness among non-nephrologists, and lack of effective clinical decision support (CDS) tools in the electronic health record (EHR).^[@bibr5-2374289518816502],[@bibr6-2374289518816502]^ A recent study confirmed lack of recognition of early AKI by nurses.^[@bibr7-2374289518816502]^ While the implementation of EHR alerts in bringing AKI to the attention of providers has come under intense scrutiny,^[@bibr6-2374289518816502],[@bibr8-2374289518816502]^ the impact of such alerts has not yet been shown to be of value.^[@bibr9-2374289518816502],[@bibr10-2374289518816502]^ Automated AKI detection algorithms using delta-checking criteria have increasingly been embedded in Laboratory Information Systems (LIS) of biochemistry laboratories,^[@bibr11-2374289518816502][@bibr12-2374289518816502][@bibr13-2374289518816502]-[@bibr14-2374289518816502]^ but the clinical value of LIS-generated alerts also remains unproven.

Incidence estimates based on hospital billing codes are more specific but less sensitive when compared to incidence estimates based on laboratory SCr criteria.^[@bibr15-2374289518816502],[@bibr16-2374289518816502]^ However, billing codes tend to capture only the more severe cases of AKI (stage 2 and 3), which account for less than 30% of all AKI episodes.^[@bibr17-2374289518816502]^ Hence, compared to laboratory data, billing codes underestimate the true disease burden and economic impact of AKI, especially early-stage disease.^[@bibr16-2374289518816502],[@bibr17-2374289518816502]^

This study was conducted as part of a quality improvement project to standardize detection of AKI within an integrated health system in New York. The clinical aim was to introduce into routine hospital practice, especially in nonspecialist settings, a comprehensive electronic laboratory AKI alerting system based on KDIGO criteria. Besides standardizing early AKI detection, we aimed to reduce variability in diagnosis by embedding this alerting system into daily clinical workflow.^[@bibr18-2374289518816502],[@bibr19-2374289518816502]^ The laboratory-triggered AKI alert was distributed in a patient-specific fashion to all inpatient units, with the requirement that such patients be evaluated promptly. Clinical documentation of AKI, through the *International Classification of Diseases* (*ICD*) coding system, was used as the primary end point and laboratory estimates of AKI severity were assessed as secondary end points to evaluate the effectiveness of daily laboratory alerting.

Methods {#section2-2374289518816502}
=======

Study Design, Setting, and Population {#section3-2374289518816502}
-------------------------------------

We performed a quasi-experimental study with a pre--post study design and interrupted time-series analysis.^[@bibr20-2374289518816502]^ The study was conducted at 8 adult hospitals within the Northwell Health System between January 1, 2014, and June 30, 2017. Although the alerting program ran in continuity, data were collected and analyzed for four 6-month intervals during this study period so as to avoid potential seasonality as a confounding factor: January 1 to June 30, 2014; January 1 to June 30, 2015; January 1 to June 30, 2016; and January 1 to June 30, 2017. For these 4 time periods; there were 65 831 discharges in 2014, 66 364 discharges in 2015, 68 889 discharges in 2016, and 68 523 discharges in 2017 at the 8 hospital sites collectively. With one exception, all sites shared the same LIS, Cerner Millennium and EHR, Sunrise Clinical Manager (Allscripts Corp, Raleigh, North Carolina). The exception was one study site which was not yet on the Cerner Millennium LIS in January to June 2014, but was by the January to June 2015 time period. This study was limited to inpatient adult medical and surgical patients greater than 18 years of age.

A health system executive committee comprising senior clinical leadership from the Department of Pathology and Laboratory Medicine, the Division of Nephrology, and the system Clinical Quality program endorsed the policy to standardize AKI detection through daily alerts.

Acute Kidney Injury Criteria and Baseline Creatinine {#section4-2374289518816502}
----------------------------------------------------

The KDIGO criteria rely on the ability to detect an incremental increase in SCr, compared to a baseline value, of 0.3 mg/dL within 48 hours and/or a 50% increase (1.5 times) within 7 days.^[@bibr1-2374289518816502]^ The KDIGO definition also suggests comparing the high inpatient SCr value to a prior stable baseline, usually an outpatient SCr measurement in a patient's normal state of health.^[@bibr1-2374289518816502]^ But, there is no consensus on what the baseline should be, and investigators have used different surrogates.^[@bibr21-2374289518816502][@bibr22-2374289518816502]--[@bibr23-2374289518816502]^ If no reliable estimate of baseline SCr can be made, the KDIGO guidelines recommend using the lowest SCr during hospitalization as the baseline.^[@bibr1-2374289518816502]^ Although there may be risk of dilutional artefact in SCr measurements if blood samples are drawn from an intravenous line, our hospital quality metrics indicate that test cancellations due to "improper collection" are rare. The most common causes of test cancellations are clotted sample (44%) or quantity not sufficient (36%); among remaining causes, "improper collection" (wrong tube type or wrong collection methodology, including dilutional artefact) were only 6% of cancelled tests, or 0.006% of total tests (data not shown). We therefore felt that use of the lowest SCr during hospitalization as the baseline was appropriate.

Laboratory Electronic Alerting for Acute Kidney Injury {#section5-2374289518816502}
------------------------------------------------------

We developed a real-time alerting system based on a structured query language algorithm run on all laboratory SCr values generated during an inpatient encounter ([Figure 1](#fig1-2374289518816502){ref-type="fig"}). Our algorithm used the delta-checking functionality within Cerner. Because of inconsistent access to prior outpatient SCr values for all hospitalized patients, the minimum inpatient SCr value was used as the baseline for this algorithm, as per KDIGO guidelines.^[@bibr1-2374289518816502]^ Initial SCr at the time of admission was included as a potential baseline value. If the baseline value decreased during admission, then the new minimum SCr became the rolling baseline. If there was a clinically significant rise consistent with KDIGO criteria, then an alert was generated and the elevated SCr result was flagged. Patients who only had a single SCr measurement during the encounter or did not meet the KDIGO criteria were not flagged.

![Electronic reporting algorithm for AKI using serum creatinine measurements. AKI, acute kidney injury; E-SCr, elevated serum creatinine; KDIGO, kidney disease improving global outcomes; LIS, laboratory information system; M-SCr, minimum serum creatinine;.](10.1177_2374289518816502-fig1){#fig1-2374289518816502}

All SCr measurements from emergency departments, admission units, intensive care units, or any other inpatient location were included. All SCr values throughout the study period were measured using Roche Cobas automated analyzers, based on the modified Jaffe Method. The coefficient of variation of the SCr assay ranged from 2.5% to 5% (normal creatinine range, 0.5-1.2 mg/dL).

Development of Acute Kidney Injury Rounding Report and Validation of Alerting System {#section6-2374289518816502}
------------------------------------------------------------------------------------

To create the daily report, the project team programmed the LIS to generate an electronic report of all AKI alerts within the previous 24 hours. A unit-specific consolidated report, with patient room and bed location, was faxed and e-mailed to clinical and nursing leads of all units at 7:00 [am]{.smallcaps} in the morning. This "rounding" report was then discussed at morning ward rounds to ensure all members of the clinical team were aware of their patients at risk for AKI. We validated the algorithm and reporting workflow at one hospital (pilot site) from January 1, 2014, to June 30, 2014. The chief medical officer (CMO) of the pilot hospital (G.B.) conducted a provider alert awareness campaign from November to December 2013, prior to the introduction of alerting system.

Intervention {#section7-2374289518816502}
------------

Despite daily AKI alerting at the pilot site for the first 6 months of 2014, preliminary analysis of billing data showed only a minimal improvement in provider documentation of AKI (Supplemental Figure 1). Starting in July 2014, and with the approval of the CMOs of the respective system hospitals, the Clinical Documentation Improvement (CDI) team and Department of Pathology and Laboratory Medicine created a system-wide partnership. At the pilot site, through July to December 2014, in addition to issuance of the rounding report to clinical units, a copy of the daily AKI rounding report was sent to the CDI specialists who received instructions to query physicians in case of inconsistent documentation of AKI. Supplemental Figure 1 shows that clinical documentation of AKI at the pilot site then began to increase. During this same time period (July to December 2014), physicians and nurses at all 8 hospitals received presentations regarding accurate clinical documentation of AKI based on KDIGO criteria, severity, etiology, and treatments. An awareness campaign for CDI specialists and medical coders at all 8 hospitals also was conducted from July to December 2014.

Data Collection and Statistical Analysis {#section8-2374289518816502}
----------------------------------------

We analyzed billing data for every hospital episode with a primary or secondary diagnosis-related groups (DRGs) diagnosis of AKI or acute tubular necrosis (ATN), which in turn are based on the 9th and 10th iterations of the *ICD Clinical Modification* (*ICD-9CM*, *ICD-10-CM*). We analyzed laboratory data on AKI alerts generated by our algorithm from the LIS database, noting that a single hospital admission can result in multiple AKI alerts. Accordingly, every hospital episode was categorized into KDIGO stages 1 to 3, as follows---stage 1: SCr increase by ≥ 0.3 mg/dL from baseline or SCr increase by 1.5 to 1.9 times baseline; stage 2: SCr increase by 2.0 to 2.9 times baseline; stage 3: SCr increase by 3.0 times baseline or SCr ≥ 4 mg/dL. Only the most severe AKI alert for each hospital episode was used for classifying laboratory data into stages 1 to 3.

Data points collected (deidentified) were age, gender, encounter number, baseline SCr result, SCr result which met the KDIGO criteria of (a) absolute rise of 0.3 mg/dL within 48 hours, (b) relative rise of 50% within 7 days, or (c) both. The institutional review board waived the need for informed patient consent because the data were collected as part of an ongoing quality improvement project.

For all hospitals, we only compared data from January 1, 2014, to June 30, 2014 (1 preintervention period) with data from January 1, 2015, to June 30, 2015, January 1, 2016 to June 30, 2016, and January 1, 2017, to June 30, 2017 (3 postintervention periods), to avoid the potential confounding effect of our educational intervention (July 1, 2014, to December 31, 2014) on data from the pilot site and to minimize the effect of seasonal variation.

All incidence estimates for billing and laboratory data were calculated using cumulative incidence methodology. The total number of hospital discharges were the denominators for incidence calculations. As noted earlier, Cerner LIS was in use at 7 of the hospitals for the full study period but was implemented in the latter half of 2014 at one of our hospitals (which was not the 2014 pilot hospital). Hence, the denominator for aggregate AKI incidence calculations from January to June 2014 for laboratory data (7 hospitals) was lower compared to billing data (8 hospitals).

The 95% confidence interval (CI) for incidence estimates was calculated assuming a normal distribution. We grouped laboratory-identified stage 1 and stage 2 AKI episodes as "early AKI" and stage 3 episodes as "late AKI." Analysis of variance was used to assess the statistical significance of data variation of the 4 study years (2014-2017). For comparisons of individual years, risk ratio (RR) and absolute risk difference (RD) were used to compare pre- and postintervention incidence estimates. For all statistical tests, *P* \< .05 was considered statistically significant; numerical *P* values are given down to *P* \< .001. Microsoft Excel (version 2013) and Minitab (version 14) were used for all analyses.

Results {#section9-2374289518816502}
=======

Incidence of Acute Kidney Injury Episodes {#section10-2374289518816502}
-----------------------------------------

### Clinical documentation {#section11-2374289518816502}

Preliminary analysis of coded *ICD* data for the pilot hospital site for the preintervention period (January 1, 2014, to June 30, 2014) showed that the incidence of AKI/ATN combined was 5.52% (509 episodes in 9213 discharges). After our definitive educational intervention (July 1, 2014, to December 31, 2014), incidence for documented AKI and ATN diagnosis improved steadily at the pilot site during the remainder of 2014, reaching 13.1% in December (1245 episodes in 9502 discharges). The monthly incidence rates in 2014 at the pilot site are shown in Supplemental Figure 1, documenting the steady rise in the second half of the calendar year, concurrent with the ongoing educational campaign.

For the 8 hospital sites, the study population consisted of a total of 269 607 adult hospital discharges (65 831 in 2014; 66 364 in 2015; 68 889 in 2016, and 68 523 in 2017). The episode counts for AKI, ATN, and AKI/ATN combined for all hospitals over the study period are given in [Table 1](#table1-2374289518816502){ref-type="table"}. When compared to preintervention period of 2014 (2965 AKI and 789 ATN episodes), the number of coded AKI and ATN episodes increased over the postintervention periods of 2015 (5523 AKI and 1040 ATN episodes), 2016 (7589 AKI and 1198 ATN episodes), and 2017 (7383 AKI and 1173 ATN episodes). The proportion of episodes coded as AKI (versus ATN) also increased: from 79.0% in 2014, to 84.2% in 2015, 86.4% in 2016, and 86.3% in 2017; corresponding proportions for ATN were 21.0% in 2014, 15.8% in 2015, 13.6% in 2016, and 13.7% in 2017. This supports the premise that a large proportion of the increased count of documented episodes was because of better detection and treatment of early-stage AKI.

###### 

Study Characteristics and Incidence of AKI Episodes by Laboratory Data and Administrative (*ICD*) Data for 8 Hospitals by Study Period.

![](10.1177_2374289518816502-table1)

  Characteristic                                                                                Preintervention Period   Postintervention Periods                                                 
  --------------------------------------------------------------------------------------------- ------------------------ -------------------------- ---------------------- ---------------------- -------
  Episodes as per clinical documentation (ICD) data                                                                                                                                               
   Discharges, count                                                                            65 831                   66 364                     68 889                 68 523                 NA
   Episodes coded as AKI, count                                                                 2965                     5523                       7589                   7383                   NA
   Proportion of episodes coded as AKI (%)                                                      2965/3754 (79.0)         5523/6563 (84.2)           7589/8787 (86.4)       7383/8556 (86.3)       NA
   Episodes coded as ATN, count                                                                 789                      1040                       1198                   1173                   NA
   Proportion of episodes coded as ATN (%)                                                      789/3754 (21.0)          1040/6563 (15.8)           1198/8787 (13.6)       1173/8556 (13.7)       NA
   Episodes coded as AKI or ATN, count                                                          3754                     6563                       8787                   8556                   NA
   Incidence (95% CI) of coded AKI episodes per 100 discharges                                  4.50 (4.34-4.66)         8.32 (8.11-8.53)           11.02 (10.79-11.25)    10.77 (10.54-11.0)     .002
   Incidence (95% CI) of coded ATN episodes per 100 discharges                                  1.20 (1.12-1.28)         1.57 (1.48-1.66)           1.74 (1.64-1.84)       1.71 (1.61-1.81)       .0130
   Incidence (95% CI) of total coded AKI and ATN episodes per 100 discharges                    5.7 (5.52-5.88)          9.89 (9.66-10.12)          12.76 (12.51-13.01)    12.49 (12.24-12.74)    .001
  Episodes as per laboratory data                                                                                                                                                                 
   Discharges, count                                                                            55 559^‡^                66 364                     68 889                 68 523                 NA
   Stage 1 AKI episodes, count                                                                  9061                     10 062                     10 891                 11 115                 NA
   Stage 2 AKI episodes, count                                                                  2103                     2381                       2369                   2656                   NA
   Stage 1 and 2 AKI episodes combined (*early AKI)*, count                                     11 164                   12 443                     13 260                 13 771                 NA
   Proportion of *early* AKI episodes (%)                                                       11 164/11 821 (94.4)     12 443/13 227 (94.1)       13 260/14 023 (94.6)   13 771/14 450 (95.3)   NA
   Stage 3 AKI episodes (*late AK*I), count                                                     657                      784                        763                    679                    NA
   Proportion of *late* AKI episodes (%)                                                        657/11 821 (5.6)         784/13 227 (5.9)           763/14 023 (5.4)       679/14 450 (4.7)       NA
   All stages AKI episodes, count                                                               11 821                   13 227                     14 023                 14 450                 NA
   Incidence (95% CI) of AKI stage 1 episodes per 100 discharges                                16.31 (16.0-16.62)       15.16 (14.89-15.43)        15.81 (15.54-16.08)    16.22 (15.94-16.5)     .903
   Incidence (95% CI) of AKI stage 2 episodes per 100 discharges                                3.79 (3.63-3.95)         3.59 (3.45-3.73)           3.44 (3.3-3.58)        3.88 (3.74-4.02)       .514
   Incidence (95% CI) of AKI stage 1 and 2 episodes combined (*early* AKI) per 100 discharges   20.1 (19.77-20.43)       18.75 (18.46-19.04)        19.25 (18.96-19.54)    20.1 (19.8-20.4)       .832
   Incidence (95% CI) of AKI stage 3 (late AKI) episodes per 100 discharges                     1.18 (1.09-1.27)         1.18 (1.09-1.27)           1.11 (1.03-1.19)       0.99 (0.92-1.06)       .438
   Incidence (95% CI) of AKI all stages combined per 100 discharges                             21.28 (20.94-21.62)      19.93 (19.63-20.23)        20.36 (20.06-20.66)    21.09 (20.79-21.39)    .404

Abbreviations: AKI, acute kidney injury; ATN, acute tubular necrosis; CI, confidence interval; *ICD*, *International Classification of Diseases*; LIS, Laboratory Information Systems; NA, not applicable.

\*All comparisons of postintervention periods (2015, 2016, and 2017) are made with the preintervention period of 2014.

^†^Analysis of variance was used to assess the statistical significance of data variation of the 4 study years (2014-2017).

^‡^The denominator for incidence calculations for laboratory data was lower for 2014 because of incomplete data: 7 of the 8 study hospitals were on the Cerner LIS at the time. For 2015 to 2017, all 8 study hospitals were on Cerner LIS.

The denominator for incidence calculations was the number of hospital discharges. For all 8 hospitals combined during the preintervention period (January to June, 2014), the incidence of AKI was 4.5% (2965 episodes in 65 831 discharges), the incidence of ATN was 1.2 % (789 episodes in 65 831 discharges), and incidence of AKI and ATN combined was 5.7% (3754 episodes in 65 831 discharges).

Beginning in January 2015, clinically documented incidence rates of AKI and ATN at all hospitals steadily increased. Documented incidence of AKI increased to 8.32% in 2015, 11.02% in 2016, and 10.77% in 2017 (*P* = .002). Similarly, documented incidence of ATN increased from 1.2% in 2014 to 1.57% in 2015, 1.74 % in 2016, and 1.71% in 2017 (*P* = .013). In aggregate (AKI and ATN), the incidence based on documented diagnoses increased significantly from 5.7% (95% CI: 5.52%-5.88%) in 2014 to 9.89% (95% CI: 9.66%-10.12%) in 2015, 12.76% (95% CI; 12.51%-13.01%) in 2016, and 12.49% (95% CI; 12.24% to 12.74%) in 2017 (*P* = .001).

### Laboratory data {#section12-2374289518816502}

For analysis of laboratory data, we categorized all hospital episodes into KDIGO stages 1 to 3 based on the most severe laboratory AKI alert for each episode. For comparison, we grouped laboratory-identified stage 1 and 2 AKI episodes as *early* AKI and stage 3 episodes as *late* AKI. Although there is no 1:1 concordance between clinical severity of AKI cases based on KDIGO criteria, with the severity of documented *ICD* diagnosis of AKI or ATN, we hypothesized that most if not all stage 3 AKI episodes would be documented as ATN based on *ICD* coding. This distinction also allowed us to compare laboratory KDIGO criteria versus *ICD* coding criteria for AKI or ATN.

[Table 1](#table1-2374289518816502){ref-type="table"} shows that, compared to 2014, and allowing for capturing laboratory data for only 7 hospitals in 2014, there was no change in the distribution of laboratory-identified stages of AKI in 2015, 2016, and 2017. Specifically, stage 1 and 2 "early" AKI contributed to 94% to 95% of all laboratory-detected episodes in all 4 years (2014-2017), with only 4% to 5% being stage 3 "late" AKI episodes.

In the preintervention, baseline period (2014), the incidence of AKI by stages was 16.31 % for stage 1, 3.79 % for stage 2, 20.1% for stage 1 and 2 combined (early AKI), 1.18 % for stage 3 (late AKI), and 21.28% for all AKI stages. The incidence of stage 1 AKI episodes decreased from 16.31% (95% CI: 16.0%-16.62%) in 2014 to 15.16% (95% CI:, 14.89%-15.43%) in 2015. However, the incidence for stage 1 episodes increased to 15.81% (95% CI: 15.54%-16.08%) in 2016 and 16.22% (95% CI: 15.94%-16.5%) in 2017 (*P* = .903). Similarly, stage 2 AKI episodes slightly reduced in incidence from 3.79% (95% CI: 3.63%-3.95%) in 2014 to 3.59% (95% CI: 3.45%-3.73%) in 2015 and 3.44% (95% CI: 3.3%-3.58%) in 2016. Similar to stage 1, the incidence of stage 2 episodes rebounded to 3.88% (95% CI: 3.74%-4.02%) in 2017 (*P* = .514). Overall, laboratory-detected early AKI episodes (stage 1 and 2 combined) reduced from 20.1% (95% CI: 19.77%-20.43%) in 2014 to 18.75% (18.46%-19.04%) in 2015. However, incidence of early AKI increased to 19.25% (95% CI: 18.96%-19.54%) in 2016 and back to 20.1% (95% CI: 19.8%-20.4%) in 2017 (*P* = .832).

The incidence of stage 3 (late AKI) remained unchanged from 1.18% (95% CI: 1.09%-1.27%) in 2014 and 2015 to 1.11 % (95% CI: 1.03%-1.19%) in 2016. Stage 3 incidence slightly reduced to 0.99% (95% CI: 0.92%-1.06%) in 2017 (*P* = .438). The total incidence (all stages combined) of laboratory-detected AKI decreased from 21.28% (95% CI: 19.63%-20.23%) in 2014 to 19.93% (95% CI: 19.63%-20.23%) in 2015, but increased again to 20.36% (95% CI: 20.06%-20.66%) in 2016 and 21.09% (95% CI: 20.79%-21.39%) in 2017 (*P* = .404).

Comparison of Incidence Estimates Between Preintervention and Postintervention Periods {#section13-2374289518816502}
--------------------------------------------------------------------------------------

For ease of comparison of incidence estimates between preintervention and postintervention periods, we calculated the risk ratio by comparing the postintervention periods of 2015, 2016, and 2017 with the control (preintervention) period of 2014 ([Table 2](#table2-2374289518816502){ref-type="table"}).

###### 

Comparison of Incidence Estimates Between Preintervention and Postintervention Periods.

![](10.1177_2374289518816502-table2)

  Variable                                                Postintervention Period From January 1, 2015, to June 30, 2015   Postintervention Period From January 1, 2016, to June 30, 2016   Postintervention Period From January 1, 2017, to June 30, 2017                                
  ------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- -------- ------------------- --------
  Episodes as per clinical documentation (*ICD*) data                                                                                                                                                                                                                                     
   Documentation of AKI                                   1.86 (1.78-1.94)                                                 \<.001                                                           2.46 (2.35-2.55)                                                 \<.001   2.39 (2.30-2.49)    \<.001
   Documentation of ATN                                   1.31 (1.19-1.43)                                                 \<.001                                                           1.45 (1.33-1.59)                                                 \<.001   1.43 (1.31-1.56)    \<.001
   Documentation of AKI and ATN combined                  1.73 (1.67-1.80)                                                 \<.001                                                           2.24 (2.16-2.32)                                                 \<.001   2.19 (2.11-2.27)    \<.001
  Episodes as per laboratory data                                                                                                                                                                                                                                                         
   Laboratory episodes, AKI stage 1                       0.93 (0.91-0.95)                                                 \<.001                                                           0.97 (0.95-0.99)                                                 .017     0.99 (0.97-1.02)    .6763
   Laboratory episodes, AKI stage 2                       0.95 (0.89-1.0)                                                  .0682                                                            0.91 (0.86-0.96)                                                 .0011    1.02 (0.97-1.08)    .4071
   Laboratory episodes, AKI stage 1 and 2 (*early* AKI)   0.93 (0.91-0.95)                                                 \<.001                                                           0.96 (0.94-0.98)                                                 .0002    1.00 (0.98-1.02)    .9897
   Laboratory episodes, AKI stage 3 (*late* AKI)          1.0 (0.9-1.11)                                                   .9851                                                            0.94 (0.84-1.04)                                                 .216     0.838 (0.75-0.93)   .0012
   Laboratory episodes, AKI all stages                    0.94 (0.92-0.96)                                                 \<001                                                            0.96 (0.94-0.98)                                                 \<.001   0.99 (0.97-1.02)    .4185

Abbreviations: AKI, acute kidney injury; ATN, acute tubular necrosis; CI, confidence interval; *ICD, International Classification of Diseases*; RR, risk ratio.

\*Comparison between the postintervention period of 2015 with preintervention period of 2014.

^†^Comparison between the postintervention period of 2016 with preintervention period of 2014.

^‡^Comparison between the postintervention period of 2017 with preintervention period of 2014.

### Clinical documentation {#section14-2374289518816502}

Compared to the preintervention period, documentation of AKI significantly increased in 2015 (RR = 1.86, *P* \< .001), 2016 (RR = 2.46, *P* \< .001), and 2017 (RR = 2.39, *P* \< .001). Similarly, documentation of ATN significantly increased in 2015 (RR = 1.31, *P* \< .001), 2016 (RR = 1.45, *P* \< .001), and 2017 (RR = 1.43, *P* \< .001). Overall, the documentation of AKI and ATN combined increased significantly and was sustained over the postintervention periods of 2015 (RR = 1.73, *P* \< .001), 2016 (RR = 2.24, *P* \< .001), and 2017 (RR = 2.19, *P* \< .001). These RR ratios corroborate the data shown in [Table 2](#table2-2374289518816502){ref-type="table"}, in which there was a \>150% increase in 2015, and \>200% increase in 2016 and 2017, of timely clinical documentation of AKI and ATN episodes when compared to 2014.

### Laboratory data {#section15-2374289518816502}

Because of laboratory alerting and education of providers, we had hoped to see a reduction in the disease burden of AKI as calculated by laboratory incidence estimates. However, as shown in [Table 2](#table2-2374289518816502){ref-type="table"}, though stage 1 episodes decreased in 2015 (RR = 0.93, *P* \< .001) and 2016 (RR = 0.97, *P* = .017), this trend was not sustained in 2017 (RR = 0.99, *P* = .6763). Similarly, stage 2 episodes decreased in 2016 (RR = 0.91, *P* \< .001), but this was not preceded by reduction in 2015 (RR = 0.95, *P* = .0682) and also not sustained in 2017 (RR = 1.02, *P* = .4071). The combined stage 1 and stage 2 (early AKI) incidence decreased in 2015 (RR = 0.93, *P* \< .001) and 2016 (RR = 0.96, *P* = .002), but this was not sustained in 2017 (RR = 1.0, *P* = .9897). Stage 3 (late AKI) episodes did not decrease in 2015 (RR = 1.0, *P* = .9851) or 2016 (RR = 0.94, *P* = .216), but did decrease in 2017 (RR = 0.838, *P* = .0012), suggesting no consistent effect. Overall, the laboratory incidence for all stages combined decreased in 2015 (RR = 0.94, *P* \< .001) and 2016 (RR = 0.96, *P* \< .001), but this effect was not sustained through 2017 (RR = 0.99, *P* = .4185). These data do not allow distinction between whether this program was or was not effective in reducing the disease burden of AKI, since we were not examining potential risks for development of AKI in this study.

Comparison of Incidence Estimates of Acute Kidney Injury Episodes Between Laboratory Data and Coded (*International Classification of Diseases*) Data {#section16-2374289518816502}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Direct comparisons of incidence estimates from laboratory-identified AKI episodes versus administratively documented AKI and ATN episodes are given in [Table 3](#table3-2374289518816502){ref-type="table"} and Supplemental Figure 2. Before intervention, the incidence of laboratory-detected AKI episodes (21.28 %) was significantly different from coded *ICD* episodes (5.7%) in 2014 (RD, 15.57%). After intervention, this gap between laboratory incidence and documented incidence narrowed in 2015 (RD, 10.05%), improved further in 2016 (RD, 7.6%) and was sustained in 2017 (RD, 8.6%). We calculate that compared to 2014 preintervention period, an additional 2809, 5033, and 4802 episodes of AKI and ATN were documented in 2015, 2016, and 2017, respectively.

###### 

Comparison of Incidence Estimates of AKI Episodes Between Laboratory Data and Coded (*ICD*) Data, Preintervention Period, and Postintervention Periods.

![](10.1177_2374289518816502-table3)

  Characteristic                                                              Preintervention Period   Postintervention Periods                         
  --------------------------------------------------------------------------- ------------------------ -------------------------- --------------------- ---------------------
  Incidence (95% CI) of AKI all stages combined per 100 discharges            21.28 (20.94-21.62)      19.93 (19.63-20.23)        20.36 (20.06-20.66)   21.09 (20.79-21.39)
  Incidence (95% CI) of total coded AKI and ATN episodes per 100 discharges   5.7 (5.52-5.88)          9.89 (9.66-10.12)          12.76 (12.51-13.01)   12.49 (12.24-12.74)

Abbreviations: AKI, acute kidney injury; ATN, acute tubular necrosis; CI, confidence interval; *ICD*, *International Classification of Diseases*.

Discussion {#section17-2374289518816502}
==========

To our knowledge, this study is the first to show how inpatient daily laboratory alerting for AKI combined with education of clinical providers (physician and nurses), CDI specialists, and medical coders significantly improved provider recognition and documentation of AKI and ATN. As the 2014 single hospital pilot demonstrated, daily laboratory alerting alone was an insufficient intervention. Communicating the risk of AKI through daily reports in a unit-targeted fashion across the entire hospital, combined with preparatory education for both providers and the administrative teams were important factors in improved recognition and documentation of AKI. A critical factor was the collaboration between the laboratory and the CDI team. The CDI specialists were the effector arm both for reaching out to the providers regarding patients at risk for AKI and for ensuring compliance with documentation. We also had the all-important support of hospital leadership at each of the 8 hospital sites.

This study presents a workflow innovation for early AKI recognition which can be replicated in other hospital settings. First, KDIGO guidelines are automated into computable CDS, using the delta-checking functionality of the LIS.^[@bibr24-2374289518816502]^ Delta check algorithms are highly sensitive and capture \>98% of patients at risk for AKI.^[@bibr3-2374289518816502],[@bibr13-2374289518816502]^ Second, alert fatigue is avoided by consolidating daily alerts into a single report for morning rounds.^[@bibr18-2374289518816502],[@bibr25-2374289518816502],[@bibr26-2374289518816502]^ Third, there is an educational focus on provider behavioral change in conjunction with implementing the daily AKI alerts.^[@bibr9-2374289518816502],[@bibr27-2374289518816502],[@bibr28-2374289518816502]^ Fourth, clinical documentation compliance is promoted by partnering with CDI professionals. Of necessity, clinical documentation demands both clinical diagnosis and appropriate clinical management. Formal AKI documentation has been associated with improved patient survival after adjusting for severity of illness.^[@bibr29-2374289518816502]^ Fifth, linkage of administrative coding data with laboratory data enables examination of the true disease burden of AKI for registry-based clinical studies.^[@bibr30-2374289518816502],[@bibr31-2374289518816502]^

This study has numerous strengths. First, the incidence of AKI based on laboratory estimates is similar to other investigations and confirms the reported gap between laboratory estimates and documented AKI diagnoses.^[@bibr4-2374289518816502],[@bibr16-2374289518816502]^ Second, our alerting system is a fully automated, low-cost solution, requiring no manual laboratory intervention.^[@bibr15-2374289518816502],[@bibr17-2374289518816502]^ Third, similar to recent reports, we show that laboratory data can be successfully used as a surveillance tool for AKI monitoring in routine hospital settings.^[@bibr3-2374289518816502],[@bibr32-2374289518816502]^

The clinically documented rates of AKI and ATN, our primary outcome of interest, improved significantly from 5.7% in 2014 to 9.89% in 2015, 12.76% in 2016, and 12.49% in 2017. This represented a substantial increase in the assignment of hospital episodes to appropriate DRG categories of AKI (comorbidity) and ATN (major comorbidity). It is reasonable to posit that improved documentation had a significant impact on the calculated case-mix index for the 8 hospitals in the study and on expected LOS and baseline mortality for reporting to regulatory agencies.

Analysis of aggregated laboratory data for all hospitals showed a slight but significant reduction in laboratory-detected AKI incidence from 21.28% in 2014 to 19.93% in 2015 and 20.36% in 2016. However, this reduction was confined to early AKI (stage 1 and 2) and the laboratory-detected AKI incidence increased again to 21.09% in 2017. These data suggest that our intervention had some desirable impact on reducing overall disease burden in 2015 and 2016 but was not sustained through 2017. Consistent sustained reduction in disease burden and progression will require more sophisticated CDS which integrates laboratory with pharmacy data in real time to modulate dosing of nephrotoxic medications, as well as algorithmic treatment approaches and development of novel biomarkers.^[@bibr9-2374289518816502],[@bibr33-2374289518816502][@bibr34-2374289518816502]-[@bibr35-2374289518816502]^

Our study has limitations. Selection of appropriate baseline SCr is an important determinant of accuracy of AKI detection algorithms. Using minimum inpatient SCr is a sensitive method for AKI detection, but it can lead to false-positives.^[@bibr4-2374289518816502],[@bibr36-2374289518816502],[@bibr37-2374289518816502]^ However, our approach was to use laboratory alerting as a screening tool to prompt earlier clinical evaluation rather than provide a diagnosis.^[@bibr8-2374289518816502]^ Since we were implementing this system across all units including nonspecialist areas, we accepted the trade-off of high sensitivity over lower specificity. Although some laboratory alerts could have been false-positive, the physicians were required to use their clinical judgment to attribute elevated SCr to AKI. Moreover, to satisfy documentation compliance, the provider needed to document the likely etiology, treatment, and additional nursing time spent in management of the patient. All these provider-driven steps would help ensure that the clinical diagnosis of AKI would have the requisite specificity.

Use of lowest SCr in intensive care settings could lead to overdetection of AKI. However, this has more to do with a lack of consensus on the best estimate for baseline creatinine in the literature.^[@bibr21-2374289518816502]^ Investigators have used varying surrogates for baseline SCr, including first inpatient value, minimum inpatient value, average of first 3 values, and an average of outpatient value within 1 year prior to hospitalizations. This lack of consensus makes comparisons difficult and sometimes impractical. According to recent literature, the best value for baseline creatinine is a patient's outpatient SCr value in a normal state of health.^[@bibr22-2374289518816502],[@bibr23-2374289518816502]^ However, this outpatient value is not available in most in-patient settings due to lack of interoperability between outpatient and inpatient EHR systems. Consequently, the outpatient SCr value is difficult to obtain and implement consistently in AKI detection algorithms. However, KDIGO guidelines recommend that, if a reliable outpatient SCr value/estimate cannot be obtained, then the next best choice for baseline is the minimum inpatient value.

Acute kidney injury occurs most commonly as a secondary diagnosis in conjunction with other common medical and surgical diagnosis. As this study was based on laboratory and administrative coding data only, we did not assess the impact of our intervention on other clinical outcome variables such as mortality and LOS. We did not have access to granular cost data for hospital episodes. Thus, the impact of our intervention on costs-of-care was not part of this study.^[@bibr17-2374289518816502],[@bibr38-2374289518816502],[@bibr39-2374289518816502]^

Although it can be argued that alerts in the EHR would be the ideal solution, such alerts do not provide a fail-safe for 2 reasons: the ever-present concern about "alert fatigue" and the requisite that a provider interact with the EHR in order to observe such an alert. A founding premise of this program was hospital medical leadership's desire to guarantee medical assessment of potential AKI patients' status at the start of every hospital day. The laboratory-based program provided the foundational data, using delta-checking functionality available within most modern LISs. Indeed, this LIS-based approach for AKI alerting is now in widespread use in the National Health Service in England.^[@bibr11-2374289518816502]^ That being said, institutional efforts to establish real-time AKI alerts within the EHR continue.

A 24-hour rounding report could lead to an alert delay of anywhere between 1 and 23 hours. However, we believe that the enhanced sensitivity of our alerting system offsets the delay in diagnosis resulting from consolidating the alerts from the previous 24 hours into a single report. Specifically, using the minimum inpatient SCr as the baseline allows our alerting algorithm to be extremely sensitive to any significant SCr fluctuations as has been demonstrated in earlier studies.^[@bibr3-2374289518816502],[@bibr4-2374289518816502]^ Also, this decision to use a once a day report was taken in conjunction with the CMOs' desire to minimize alert fatigue and optimize provider focus on AKI as a clinical parameter. The fact that clinical recognition of AKI increased, as monitored by coding for this condition, provides assurance that the chosen strategy was of value.

Although the total laboratory incidence of AKI/ATN declined in 2015 and 2016, there was rebound in laboratory disease burden in 2017. This possibly could have been due to unanticipated and unwelcome provider behavioral change of not paying attention to laboratory values over the course of a day and depending solely on the daily alert. However, many studies indicate that isolated laboratory or EHR alerting is not sufficient factor to reduce inpatient AKI morbidity.^[@bibr27-2374289518816502],[@bibr33-2374289518816502],[@bibr40-2374289518816502]^ A comprehensive approach involving algorithmic, step-wise treatment plans including proper fluid management and medication reconciliation is necessary for treatment of AKI and prevention of progression to severe stage 3 injury.

In our study, there was a reduction in severe stage 3 episodes in 2017. This leads us to believe that providers did benefit from the daily notification, countering the argument that provider inattention may have been a consequence of this alerting program. Although severe stage 3 AKI episodes can lead to chronic kidney disease (CKD) postdischarge, we do not currently have longitudinal postdischarge data to evaluate whether long-term CKD has been reduced, owing to the current lack of an electronic master patient index in our LIS and EHR systems. This prohibited accurate linkage of inpatient to outpatient laboratory data for longitudinal follow-up of patients. Patients who suffer AKI in hospitals have a much higher risk of developing long-term CKD. Similarly, patients with preexisting CKD are more likely to develop AKI when admitted to hospitals.^[@bibr40-2374289518816502]^ In the latter instance, our data did not identify patients with preexisting CKD who may have a higher baseline SCr and may thus have been misclassified on the basis of their admission SCr values. However, it is now increasingly believed that AKI and CKD are not separate conditions but a spectrum of disorders.^[@bibr40-2374289518816502]^ Also, there are inherent limitations in the current definitions of AKI and CKD, which categorize patients into distinct categories, when they can be superimposed on each other.

Conclusions {#section20-2374289518816502}
===========

Laboratory data remain an underutilized resource for detection of AKI in routine hospital settings. We show how laboratory reporting of AKI can be used to augment administrative coding data in the detection of AKI and demonstrate the impact of laboratory reporting on improved clinical documentation. Simultaneously, we demonstrate the importance of linking a laboratory-based program with education of clinical providers and their administrative support personnel to achieve a sustained and significant increase in the recognition and clinical documentation of AKI.
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